natgillin/translations-raw huggingface dataset:
a first domain comprising a binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for an epitope (1), 
prvu domenu koja sadrži područje vezanja varijabilne domene lakog lanca prvog imunoglobulina (VL1) specifičnog za epitop (1),
a second domain comprising a binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for an epitope (2), and 
drugu domenu koja sadrži područje vezanja varijabilne domene teškog lanca drugog imunoglobulina (VH2) specifičnog za epitop (2), i
the second polypeptide chain comprises, in the N-terminal to C-terminal direction: 
drugi polipeptidni lanac sadrži, u smjeru od N-terminalnog kraja do C-terminalnog kraja:
a fourth domain comprising a binding region of a light chain variable domain of the second immunoglobulin (VL2) specific for the epitope (2), 
četvrtu domenu koja sadrži područje vezanja varijabilne domene lakog lanca drugog imunoglobulina (VL2) specifičnog za epitop (2),
which fourth domain and fifth domain are covalently linked such that the fourth domain and fifth domain do not associate together to form the epitope (1) binding site or the epitope (2) binding site; 
navedena četvrta domena i peta domena su kovalentno povezane tako da se četvrta domena i peta domena međusobno ne udružuju da tvore mjesto vezanja epitopa (1) ili mjesto vezanja epitopa (2);
wherein the second domain and the fourth domain associate together to form a binding site (VL2)(VH2) that binds the epitope (2). 
pri čemu se druga domena i četvrta domena međusobno udružuju da tvore mjesto vezanja (VL2)(VH2) koje veže epitop (2).
The diabody molecule of claim 1 or 2, wherein the second polypeptide chain additionally comprises a sixth domain, wherein the sixth domain is an Fc domain, and wherein the sixth domain is linked to the charged polypeptide domain, or the sixth domain is linked to the N-terminus of the fourth domain. 
Molekula diatijela prema zahtjevu 1 ili 2, naznačena time što drugi polipeptidni lanac dodatno obuhvaća šestu domenu, pri čemu je šesta domena Fc domena, i pri čemu je šesta domena vezana za nabijenu polipeptidnu domenu, ili je šesta domena vezana za N-terminalni kraj četvrte domene.
The diabody molecule of claim 1 or 2, wherein the diabody molecule additionally comprises a third polypeptide chain and a fourth polypeptide chain, the third and fourth polypeptide chains being covalently bonded to one another, wherein: 
Molekula diatijela prema zahtjevu 1 ili 2, naznačena time što molekula diatijela dodatno obuhvaća treći polipeptidni lanac i četvrti polipeptidni lanac, te su treći i četvrti polipeptidni lanci kovalentno vezani jedan na drugi, pri čemu:
the third polypeptide chain comprises, in the N-terminal to C-terminal direction: 
treći polipeptidni lanac sadrži, u smjeru od N-terminalnog kraja do C-terminalnog kraja:
a seventh domain comprising a binding region of a light chain variable domain of a third immunoglobulin (VL3) specific for an epitope (3), 
sedmu domenu koja sadrži područje vezanja varijabilne domene lakog lanca trećeg imunoglobulina (VL3) specifičnog za epitop (3),
a ninth domain, wherein the ninth domain is an Fc domain; 
devetu domena, pri čemu deveta domena je Fc domena;
which seventh domain and eighth domain are covalently linked such that the seventh domain and eighth domain do not associate together to form an epitope (3) binding site or an epitope (4) binding site; 
navedena sedma domena i osma domena su kovalentno povezane tako da se sedma domena i osma domena međusobno ne udružuju da tvore mjesto vezanja epitopa (3) ili mjesto vezanja epitopa (4);
the fourth polypeptide chain comprises, in the N-terminal to C-terminal direction: 
četvrti polipeptidni lanac sadrži, u smjeru od N-terminalnog kraja do C-terminalnog kraja:
a tenth domain comprising a binding region of a light chain variable domain of the fourth immunoglobulin (VL4) specific for the epitope (4), 
desetu domenu koja sadrži područje vezanja varijabilne domene lakog lanca četvrtog imunoglobulina (VL4) specifičnog za epitop (4),
The diabody molecule of claim 1, wherein the first polypeptide chain additionally comprises: 
Molekula diatijela prema zahtjevu 1, naznačena time što prvi polipeptidni lanac dodatno sadrži:
The diabody molecule of claim 8, wherein the albumin-binding domain (ABD) of the streptococcal protein G is albumin-binding domain 3 (ABD3) of protein G of Streptococcus strain G 148. 
Molekula diatijela prema zahtjevu 8, naznačena time što domena vezanja albumina (ABD) streptokoknog proteina G je albumin-vezujuća domena 3 (ABD3) proteina G soja Streptococcus G 148.
The diabody molecule of claim 13, wherein the tumor-associated antigen is a breast cancer antigen, an ovarian cancer antigen, a prostate cancer antigen, a cervical cancer antigen, a pancreatic carcinoma antigen, a lung cancer antigen, a bladder cancer antigen, a colon cancer antigen, a testicular cancer antigen, a glioblastoma cancer antigen, an antigen associated with a B cell malignancy, an antigen associated with multiple myeloma, an antigen associated with non-Hodgkin's lymphoma, or an antigen associated with chronic lymphocytic leukemia. 
Molekula diatijela prema bilo kojem od zahtjeva 1-12, naznačena time što se molekula diatijela veže na antigen povezan s tumorom. Molekula diatijela prema zahtjevu 13, naznačena time što antigen povezan s tumorom je antigen karcinoma dojke, antigen karcinoma jajnika, antigen karcinoma prostate, antigen karcinoma vrata maternice, antigen karcinoma gušterače, antigen karcinoma pluća, antigen karcinoma mjehura. antigen karcinoma debelog crijeva, antigen karcinoma testisa, antigen karcinoma glioblastoma, antigen povezan s malignitetom B stanica, antigen povezan s multiplim mijelomom, antigen povezan s ne-Hodgkinovim limfomom, ili antigen povezan s kroničnom limfocitnom leukemijom.
Apparatus as in claim 4, characterized in that each phase sub-module (34R, 34S, 34T) is connected with a star connection and the star centers of the individual power phase sub-modules (34R, 34S, 34T) are connected to each other to a neutral (N). 
Uređaj prema patentnom zahtjevu 1, naznačen time što je svaki od faznih pod-modula (34R, 34S, 34T) spojen sa zvjezdastim spojem i zvijezda je središte pojedinačnih pod-modula (34R, 34S, 34T) međusobno spojenih na nulu (N).
Method as in claim 10 or 11, characterized in that during said detection it provides to detect an arc current (IA) and an arc voltage (UA). 
Postupak prema patentnom zahtjevu 10 ili 11, naznačen time što navedene detekcije omogućuje detektiranje struje luka (IA) i napona luka (UA).
Method as in claim 12, characterized in that the activation of the positioning device (46) is commanded by an electrode control device (44) as a function of the arc voltage (UA) and the reference voltage (UR) received. 
Postupak prema patentnom zahtjevu 12, naznačen time što se aktiviranjem uređaja za pozicioniranje (46) upravlja preko uređaja za upravljanje elektrodom (44) kao funkcije napona luka (UA) i primljenog referentnog napona (UR).
a permeability enhancing agent selected from sodium caprylate, sodium caprate, sodium laurate and sodium oleate or 
sredstvo za povećanje propusnosti odabrano od natrijevog kaprilata, natrijevog kaprata, natrijevog laurata i natrijevog oleata ili
a base selected from organic base, inorganic base, phosphate buffer and salt of carboxylic acid comprising less than 5 carbon atoms or a mixture thereof 
bazu odabrane iz organske baze, neorganske baze, fosfatnog pufera i soli karboksilne kiseline koja sadrži manje od 5 atoma ugljika ili
The formulation according to claim 1, wherein halide is chloride. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu je halogenid klorid.
The formulation according to claim 1, wherein carboxylate ion is caprate. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu je karboksilatni ion kaprat.
The formulation according to claim 1, wherein permeability enhancing agent is sodium caprate. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu je sredstvo za povećanje propusnosti natrijev kaprat.
The formulation according to claim 1 or 4, wherein a permeability enhancing agent is present in an amount from 0.02% to 75% w/w of total formulation; preferably in an amount from 2.5% to 60% w/w of total formulation; most preferably in an amount from 5% to 30% w/w of total formulation. 
Formulacija sukladno patentnom zahtjevu 1 ili 4, pri čemu je sredstvo za povećanje propusnosti prisutno u količini od 0,02 do 75 težinskih postotka ukupne formulacije; poželjno u količini od 2,5 do 60 težinskih postotaka ukupne formulacije; najpoželjnije u količini od 5 do 30 težinskih postotaka ukupne formulacije.
The formulation according to claim 1, wherein organic base is selected from meglumine and Arginine. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu je organska baza izabrana između meglumina i arginina.
The formulation according to claim 1, wherein compound of formula (I) and a permeability enhancing agent is in the form of conjugate. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu je spoj formule (I) i sredstvo za poboljšavanje propustljivosti u obliku konjugata.
The formulation according to claim 1, wherein formulation comprises from 150 mg to 1500 mg of compound of formula (I) or its co-crystal. 
Formulacija sukladno patentnom zahtjevu 1, pri čemu formulacija sadrži od 150 mg do 1500 spoja formule (I) ili njegovog kokristala.
The formulation according to claim 12, wherein formulation comprises from 250 mg to 750 mg of compound of formula (I) or its co-crystal. 
Formulacija spoja formule (I) ili njegovog kokristala.12, pri čemu formulacija sadrži od 250 mg do 750 mg spoja formule (I) ili njegovog kokristala.
and R3 are independently selected from hydrogen and C1-6alkyl; 
i R3 su neovisno odabrani iz vodika i C1−6alkila;
Y and Q are independently selected from CH and N; 
Y i Q su neovisno odabrani iz CH i N;
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 
ili njegova farmaceutski prihvatljiva sol, enantiomer ili dijastereomer.
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 
ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
A compound of formula (I) according to claim 5, wherein R1 is phenyl, bromophenyl, chlorophenyl, cyanophenyl, cyclopropylphenyl, difluorophenyl, difluoromethylphenyl, fluorophenyl, fluorochlorophenyl, fluoromethylphenyl, hydroxyphenyl, methoxyphenyl, methylphenyl, trifluoromethoxyphenyl or trifluoromethylphenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 
Spoj formule (I) prema patentnom zahtjevu 5, naznačen time, da R1 je fenil, bromofenil, klorofenil, cijanofenil, ciklopropilfenil, difluorofenil, difluorometilfenil, fluorofenil, fluoroklorofenil, fluorometilfenil, hidroksifenil, metoksifenil, metilfenil, trifluorometoksifenil ili trifluorometilfenil; ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
and R3 are independently selected from hydrogen and methyl with the proviso that R2 is not methyl when R3 is H; 
i R3 su neovisno odabrani iz vodika i metila, pod uvjetom da R2 nije metil kada R3 je H;
Q is N; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 
Q je N; ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
A compound of formula (I) according to any one of claims 23 to 29, wherein R4 is difluoromethylpyridinyl, fluorochlorophenyl, difluorodifluoromethylphenyl or trifluorophenyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 
Spoj formule (I) prema bilo kojem od patentnih zahtjeva 23 do 29, naznačen time, da R4 je difluorometilpiridinil, fluoroklorofenil, difluorodifluorometilfenil ili trifluorofenil; ili njegova farmaceutski prihvatljiva sol, njegov enantiomer ili dijastereomer.
the reaction of a compound of formula (X), with halide via Suzuki-Miyaura reaction; 
reakciju spoja formule (X), s halidom putem reakcije Suzuki-Miyaura;
and R6 together with the nitrogen atom they are attached to form a 3-7 membered heterocyclyl, and R7 is aryl or heteroaryl. 
i R6 zajedno s atomom dušika na kojega su vezani, formiraju 3-7-člani heterociklil, a R7 je aril ili heteroaril.
A composition comprising a bacterial strain of the genus Blautia hydrogenotrophica having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract in the treatment or prevention of diarrhea. 
Sastav koji obuhvaća bakterijski soj roda Blautia hydrogenotrophica koji ima 16s rRNK sekvencu koja je najmanje 95% identična sa SEQ ID NO:5, za upotrebu u liječenju infekcija koje su uzrokovane patogenim Enterobacteriaceae u gastrointestinalnom traktu.
The composition for use of any preceding claim, wherein the composition is for oral administration; and/or 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu je sastav za oralno davanje.
A compound according to claim 1 which is 3-[[6-(1,3-benzodioxol-5-yl)-3-methyl-pyridine-2-carbonyl]amino]-2,4-dimethyl-benzoic acid; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-[[6-(1,3-benzodioksol-5-il)-3-metilpiridin-2-karbonil]amino]-2,4-dimetilbenzojeva kiselina; ili njezina farmaceutski prihvatljiva sol.
The Ang2-binding molecule according to claim 2, wherein said VHH consists of an immunoglobulin single variable domain having a sequence consisting of SEQ ID NO: 166. 
The Ang2-vezujuća molekula u skladu sa zahtjevom 2, naznačena time, da se navedena VHH sastoji od jednostruke varijabilne domene imunoglobulina koja ima sekvencu koja se sastoji od SEQ ID NO: 166.
The Ang2-binding molecule according to any one of claims 1 to 3, wherein said VHH or said immunoglobulin single variable domain has a modification or exchange on its N-terminus, wherein said modification is a deletion of the first amino acid and said exchange is a replacement of the first amino acid by another amino acid. 
The Ang2-vezujuća molekula prema bilo kojem od zahtjeva 1 do 3, naznačena time, da navedena VHH ili navedena jednostruka varijabilna domena imunoglobulina ima modifikaciju ili izmjenu na svojem N-završetku, gdje je navedena modifikacija zapravo odstranjivanje prve aminokiseline a navedena izmjena je zamjena prve aminokiseline s nekom drugom aminokiselinom.
The pharmaceutical composition according to claim 9, further comprising one or more additional therapeutic agents. 
Farmaceutski sastav prema zahtjevu 9, naznačen time, da nadalje obuhvaća jedno ili više dodatnih terapeutskih sredstava.
The pharmaceutical composition according to claim 11 for use in the treatment of cancer and cancerous diseases. 
Farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava u liječenju raka i kancerogenih bolesti.
The pharmaceutical composition according to claim 11 for use in the treatment of eye diseases. 
Farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava u liječenju bolesti oka.
The pharmaceutical composition for use of claim 13, wherein said eye disease is age-related macular degeneration or diabetic retinopathy. 
Farmaceutski sastav za uporabu prema zahtjevu 13, naznačen time, da se kod navedene bolesti oka radi o staračkoj makularnoj degeneraciji ili dijabetičkoj retinopatiji.
The pharmaceutical composition according to claim 11 for use in the treatment of chronic kidney diseases. 
Farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava u liječenju kroničnih bolesti bubrega.
A fitting according to claim 1, characterized in that said male and female connectors (2, 3) are in communication with each another to define an open flow passage through the fitting (I, V). 
Cjevasti spoj prema patentnom zahtjevu 1, naznačen time da su navedeni muški i ženski konektor (2,3) u komunikaciji jedan sa drugim tako da određuju otvoren prolaz za protok kroz Cjevasti spoj (I, V).
A fitting according to claim 4, characterized in that at least one of said male and female connectors (2, 3) has a transverse partition (20; 21) for closing the flow through said fitting (IV). 
Cjevasti spoj prema patentnom zahtjevu 4, naznačen time da najmanje jedan od navedenih muških i ženskih konektora (2, 3) ima poprečnu pregradu (20; 21) za zatvaranje protoka kroz navedeni cjevasti spoj (IV).
A video decoding apparatus comprising: 
Uređaj za dekodiranje videa za dekodiranje trenutne slike videa koji sadrži:
The composition of claim 1, wherein the Enterobacteriaceae is E. coli. 
Sastav za upotrebu prema zahtjevu 1, pri čemu je Enterobacteriaceae E. coli.
The composition of claim 1 or claim 2, wherein the composition is for use in treating or preventing diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis. 
Sastav za upotrebu prema zahtjevu 1 ili zahtjevu 2, gdje je sastav za upotrebu u liječenju ili prevenciji dijareje, gastroenteritisa, infekcije urinarnog trakta ili neonatalnog meningitisa.
The system of claim 6, wherein the compliance means is provided with an on-board storage for storing the location-based imposed speed limit and the current speed of the vehicle at a first time, and wherein the vehicle is provided with speed determining means for calculating or determining a second current speed of the vehicle at a second time, wherein the deceleration is determined by the compliance means on the basis of the difference between the second speed of the vehicle and the first speed of the vehicle and the difference between the second time and the first time. 
Sustav prema zahtjevu 6, naznačen time što je sredstvo za usklađivanje (30) predviđeno s uređajem za pohranjivanje (22) radi pohranjivanja ograničenja brzine nametnutog na temelju lokacije i trenutne brzine vozila (2) u prvom vremenskom trenutku, te pri čemu je vozilo opremljeno sa sredstvom za određivanje brzine (8) za izračunavanje ili određivanje druge trenutne brzine vozila u drugom vremenskom trenutku, pri čemu je usporavanje ili ubrzavanje određeno sredstvom za usklađivanje na temelju razlike između druge brzine vozila i prve brzine vozila i razlike između drugog vremenskog trenutka i prvog vremenskog trenutka.
a generating step for generating a control signal responsive to the result of the comparing step, the control signal indicates if the first current speed of the vehicle exceeds the location-based imposed speed limit, wherein the control signal is adapted to one of: provide a warning, automatically control the current speed of the vehicle, or a combination thereof; and a compliance step for monitoring a response of the vehicle to the control signal and for determining a compliance if the user or vehicle complies with the control signal, and, if the user or vehicle complies with the control signal, generating a compliance signal, and/or, if the user or vehicle does not comply with the control signal, generating a non-compliance signal. 
korak generiranja radi generiranja kontrolnog signala koji odgovara na rezultat koraka uspoređivanja, pri čemu je kontrolni signal prilagođen jednom od: pružanja upozorenja, automatske kontrole trenutne brzine vozila, ili njihovoj kombinaciji; i korak usklađivanja za praćenje usklađenosti korisnika ili vozila s kontrolnim signalom pri čemu se odgovor prati u unaprijed određenom vremenskom razdoblju, te postavljanje vremenskog praga koji označava vrijeme za koje korisnik ili vozilo treba odgovoriti na kontrolni signal; te pri čemu korak usklađenosti uključuje uspoređivanje prve trenutne brzine vozila određene u prvom vremenskom trenutku s drugom trenutnom brzinom vozila koja je određena u drugom vremenskom trenutku, te je drugi trenutak kasniji od prvog trenutka.
A method of inducing a host immune response against a Staphylococcus aureus strain, comprising administering to a subject in need of the immune response an effective amount of the composition of claim 17 . 
Pripravak prema zahtjevu 11 naznačen time što se koristi u postupku induciranja imunog odgovora domaćina protiv soja Staphylococcus aureus, koji se sastoji od primjene djelotvorne količinu navedenog pripravka na subjekta kojem je potreban imunološki odgovor.
wherein: PB1 represents a polybutadiene block comprising a 1,4-cis structure; 
– PB1 odgovara polibutadienskom bloku koji ima 1,4-cis strukturu;
PB2 represents a polybutadiene block comprising a 1,2 syndiotactic structure having a content of syndiotactic triads ranging from 60% to 80%; 
– PB2 odgovara polibutadienskom bloku koji ima 1,2 sindiotaktičku strukturu; koji ima sadržaj 1,4-trans jedinica manji od 3%, molarno.
upon infrared analysis, has bands typical of the 1,4-cis and 1,2 sequences centered at 737 cm−1 and 911 cm−1, respectively; and 
– kod infracrvene analize (FT-IR), pojaseve tipične za nizove 1,4-cis i 1,2, centrirane na 737 cm–1 odnosno na 911 cm–1;
The stereoregular diblock polybutadiene according to claim 1, which has a polydispersion index PDI corresponding to a Mw/Mn ratio ranging from 1.9 to 2.2, where Mw is a weight average molecular weight and Mn is a number average molecular weight. 
Stereoregularni diblok polibutadien u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni stereoregularni diblok polibutadien ima indeks polidisperzije (PDI) koji odgovara omjeru Mw/Mn (Mw = težinski uprosječena molekulska težina; Mn = brojevno uprosječena molekulska težina) u rasponu od 1,9 do 2,2.
The stereoregular diblock polybutadiene according to claim 1, which has a weight average molecular weight Mw ranging from 100,000 g/mol to 800,000 g/mol. A process for preparing the stereoregular diblock polybutadiene according to claim 1, the process comprising: 
Stereoregularni diblok polibutadien u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni stereoregularni diblok polibutadien ima težinski uprosječenu molekulsku težinu (Mw) u rasponu od 100.000 g/mol do 800.000 g/mol.
Y represents a divalent group —(CH2)n—, wherein n is an integer ranging from 1 to 5; or a divalent group —NR6— wherein R6 represents a hydrogen atom, or a linear or branched C1-C20 alkyl group; or a divalent group —(CH2)m—R′—(CH2)m— wherein R′ represents an aryl group optionally substituted, and m is 0, 1 or 2; 
– Y predstavlja dvovalentnu skupinu -(CH2)n-, gdje je n cijeli broj u rasponu od 1 do 5; ili dvovalentnu skupinu -NR6-, gdje R6 predstavlja atom vodika, ili nerazgranatu ili razgranatu C1-C20 alkilnu skupinu, poželjnije atom vodika; ili dvovalentnu skupinu -(CH2)m-R’-(CH2)m-, gdje R’ predstavlja izborno supstituiranu arilnu skupinu;
Al(X′)n(R8)3-n (III) wherein X′ represents a halogen atom; R8 is a linear or branched C1-C20 alkyl group, a cycloalkyl group or an aryl group, said groups being optionally substituted with one or more silicon or germanium atoms; and n is an integer ranging from 0 to 2. 
Al(X’)n(R8)3-n (III) gdje X’ predstavlja atom halogena, poput klora, broma, joda, fluora; R8 se bira između nerazgranatih ili razgranatih C1-C20 alkilnih skupina, cikloalkilnih skupina, arilnih skupina, gdje su navedene skupine izborno supstituirane s jednim ili više atoma silicija ili germanija; i n je cijeli broj u rasponu od 0 do 2.
Ph is phenyl optionally substituted; 
– Ph je izborno supstituirani fenil;
Packing for a condom as claimed in claim 1, characterized in that, the opening line is straight or zigzagged. 
Pakiranje za kondom u skladu s patentnim zahtjevom 1, naznačeno time što je linija otvaranja ravna ili vijugava.
with the proviso that (5-piperidin-1-ylmethyl-thiazol-2-yl)-carbamic acid methyl ester is excluded. 
pod uvjetom da je isključen metil ester (5-piperidin-1-ilmetil-tiazol-2-il)-karbaminske kiseline.
with the proviso that R3 and R5 denote A is excluded. 
pod uvjetom da R3 i R5 koji označavaju A je isključen.